Abstract
Considering teratogenic risk, recent data suggest that selective serotonin reuptake inhibitors (SSRIs) can be prescribed during pregnancy, even though some SSRIs are to be considered as a second choice. In any case, antidepressive treatment during pregnancy must be carefully tailored to the pregnant woman, considering absolute risk/benefit ratio of SSRIs, but also availability of other effective treatments, as well as woman's preferences.
MeSH terms
-
Abnormalities, Drug-Induced / prevention & control
-
Adult
-
Antidepressive Agents, Second-Generation / administration & dosage
-
Antidepressive Agents, Second-Generation / adverse effects
-
Antidepressive Agents, Second-Generation / therapeutic use*
-
Depression / drug therapy*
-
Depression / epidemiology
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Italy / epidemiology
-
Pregnancy
-
Prenatal Exposure Delayed Effects / prevention & control
-
Prevalence
-
Risk Assessment
-
Selective Serotonin Reuptake Inhibitors / administration & dosage
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Treatment Outcome
Substances
-
Antidepressive Agents, Second-Generation
-
Serotonin Uptake Inhibitors